RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases.

Ann Surg Oncol · 2023 · PMC9807544 · PMID 36400886

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

12 , 13 In our study, BRAF V600 mutation status showed a trend towards predicting poorer OS, however, the sample size was too small to draw definitive conclusions.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.